急性卒中血管内取栓:资格标准演变与辅助治疗
血管内取栓是缺血性卒中的标准治疗,过去十年随机试验已将资格标准扩展至包括大缺血核心患者。但许多患者尽管大血管再通率高仍预后不良,需超越恢复大血管血流的策略。动脉内溶栓和细胞保护剂正在研究中,旨在减少取栓期间及之后的继发并发症,其效果取决于作用机制与患者病理生理的对齐。
要点
- 取栓资格标准已扩展至大缺血核心等更广泛人群。
- 大血管再通率高但许多患者预后仍不良。
- 动脉内溶栓和细胞保护剂是正在研究的辅助策略。
核心结论
- 血管内取栓是缺血性卒中标准治疗,资格标准已扩展至更广泛人群,但许多患者仍预后不良。
- 需超越恢复大血管血流的策略,动脉内溶栓和细胞保护剂等辅助治疗正在研究中。
研究设计与样本
- 综述性文章,总结过去十年随机试验对取栓资格标准的扩展及辅助治疗研究进展。
主要发现
- 过去十年随机试验已将取栓资格标准扩展至包括大缺血核心卒中在内的更广泛患者人群。
- 许多患者尽管大血管再通率高仍预后不良。
- 动脉内溶栓和细胞保护剂针对微血管阻塞、兴奋性毒性、氧化应激和炎症等机制进行研究。
临床怎么用
- 辅助策略的效果取决于作用机制与患者潜在病理生理的对齐。
- 将转化研究教训纳入 refined 纳入标准和未来研究,可能改善高危患者(严重残疾或死亡)的照护。
局限性
- 细胞保护试验的临床转化受限,尽管多年结果有希望。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Endovascular thrombectomy is the standard treatment for ischaemic stroke, a leading cause of disability worldwide. Randomised trials in the past decade have expanded eligibility criteria to include broader patient populations, such as those with large ischaemic core stroke. However, many patients still have poor outcomes despite high rates of macrovascular reperfusion, underscoring the need for strategies that go beyond restoring large-vessel flow. Intra-arterial thrombolysis and cytoprotective agents are under investigation for their potential to reduce secondary complications during and after endovascular thrombectomy. These strategies target key mechanisms such as microvascular obstruction, excitotoxicity, oxidative stress, and inflammation. Their effectiveness depends on aligning the mechanism of action with the patient's underlying pathophysiology. Despite years of promising results limited by constrained clinical translation in cytoprotective trials, recent trials have provided hope and insights, helping to define crucial factors for translational success. Incorporating these lessons into refined inclusion criteria and future studies has the potential to transform our approach to caring for patients at the greatest risk of poor clinical outcomes, including severe disability or death.
引用
- Glavan M, Liu J, Sampaio Silva G, et al. Endovascular thrombectomy for acute stroke: evolving eligibility criteria and adjunct therapies. Lancet Neurol. 2026. PMID: 41389830. doi:10.1016/S1474-4422(25)00356-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。